The drug dizin for the treatment and prevention of gynecological diseases in cows

 

(57) Abstract:

Usage: veterinary medicine. The inventive product as the active compounds contains dioxidine in the number of 0.74-0.79% of the volume and neomycin sulfate to 1.22 - 1.26% of the volume, the rest of the gelatin-glycerin base. The finished preparation in the form of pessaries injected cows intrauterine depending on the severity of the pathological process in 3-5 pieces on one introduction every 8-12 hours until the closing of the cervix. With the preventive purpose of the drug is administered once. table 1.

The invention relates to veterinary pharmacology, in particular drugs for the treatment and prevention of gynecological diseases in cows.

Well-known medication for the treatment and prevention of gynecological diseases in cows, containing furazolidone, citric acid, gelatin, glycerin and distilled water (1).

The disadvantage of this drug is its low efficiency due to the acquisition of resistance to it microflora.

Also known medication for the treatment and prevention of gynecological diseases in cows "Metrosat" containing dioxidine, gelatin, glycerin and distilled water (2).

The aim of the invention is to develop cheaper and more effective drug.

This goal is achieved by the fact that the preparation additionally contains neomycin sulfate in the following ratio, wt.%:

Dioxidine - 0,74 - 0,79

Neomycin sulfate - 1,22 - 1,26

Gelatin - 15,65 - 15,79

Glycerin - 46,09 - 49,47

Distilled water - the Rest.

The invention is illustrated by the following examples.

Example 1.

The drug is made in the form of pessaries. To do this on a technical scale (per 10 kg) weighed 0,076 kg dioksidina, 0,124 kg neomycin sulfate, 1,571 kg of gelatin, 4,762 kg of glycerol. Measure the calculated amount of distilled water (3,467 l) and mixed with half its volume of glycerol. Water-glycerin mixture is heated to 85oC and after 5-10 min it make gelatin, which is stirred for 1 h before melting at a temperature of 75-85oC. To cool to 60oC in gelatin-glycerin weight make the second half of the volume of distilled water, dioxidine and neomycin sulphate, again mix until smooth for 20-30 min at 60oC by feeding on them chilled water and after solidification in the form of pessaries choose one of them, Packed in 10, 15 or 20 pcs. in plastic wrap.

One pessary finished product contains 0.08 g dioksidina and 0.13 g of neomycin sulfate.

Example 2.

The drug is manufactured analogously to example 1, using the following mass ratios of its components, wt.%:

Dioxidine - 0,79

Neomycin sulfate - 1,26

Gelatin - 15,79

Glycerin - 49,47

Distilled water - the Rest.

One pessary finished product contains 0.075 g dioksidina and 0,120 g of neomycin sulfate.

Example 3.

The drug is manufactured analogously to example 1,using the following mass ratios of its components, wt.%:

Dioxidine - 0,74

Neomycin sulfate - 1,22

Gelatin - 15,65

Glycerin - 46,09

Distilled water - the Rest.

One pessary finished product contains of 0.085 g dioksidina and 0,140 g of neomycin sulfate.

Gynecological pessaries have a conical or cylindrical shape with a pointed end from light brown to time 9,5-11,5, The preparation should be stored in a dry, protected from light place at a temperature not exceeding 20oC. shelf Life 1 year

Example 4.

Treatment of cows, patients with acute endometritis, 5), followed by samples of the proposed drug content in one pessaries dioksidina 0,07-0,09 g neomycin sulfate 0,11-0,15 g, manufactured industrially. A control group of infected animals treated with the drug on the basis of furazolidone (basic preparation). Pessaries enter intrauterine 4 pieces 2-3 times at intervals of 8-12 h before recovery. Establish that side effects and complications of the proposed remedy does not cause. Data on the effectiveness of the treatment of gynecologic preparations is presented in table.

The table shows that the additional introduction of the drug neomycin sulfate promotes its therapeutic efficacy and has a higher effect compared with the reference drug on the basis of furazolidone.

The highest effect is achieved in the proposed drug content 1 pessaries 0,075 - 0,090 g dioksidina and 0,120-0,150 g of neomycin sulfate.

Most suitable for application in practice should be considered in the preparation>/P>The drug is ready to be used in veterinary practice for the treatment and prevention of inflammation of the uterus of the cow after complicated and pathological childbirth in acute postpartum catarrhal, purulent-catarrhal endometritis, after manual separation of the placenta, uterine prolapse, caesarean section, when metritis various severity of the inflammatory process.

The drug is used intrauterine depending on the severity of the pathological process 4-5 pessaries one introduction every 8-12 hours until the closing of the cervix.

With the preventive purpose of the drug is administered once.

The use of the proposed drug in veterinary practice can improve the effectiveness of interventions for the prevention and treatment of gynecological diseases in cows.

The sources of information.

1. Worms D. K. and other Drugs in veterinary medicine. M.: Kolos, 1977, S. 341.

2. Patent USSR N 1772917, class A 61 K 31/00, 1995.

Drug for the treatment and prevention of gynecological diseases in cows, containing dioxidine, gelatin, glycerin and distilled water, characterized in that it additionally contains neomycin sulfate in the following ratio is n 46,09 49,47

Distilled water Ostalnoe

 

Same patents:

The invention relates to medicine, in particular to the areas of rheumatology and pharmacy

The invention relates to medicine, in particular to the areas of rheumatology and pharmacy
The invention relates to the field of Bioorganic chemistry and molecular biology and can be used to obtain oligo(poly)nucleotides and biologically active proteins that carry bootieful group

The invention relates to new chemical compounds with valuable properties, in particular to piperidinylmethyl derived chromane General formula (I)

< / BR>
where A is hydrogen or lower alkoxy,

E is hydrogen, hydroxyl, phenyl or piperidyl,

G phenyl not substituted or substituted with halogen and/or trifluoromethyl, fenoxaprop substituted by trifluoromethyl, benzyl, substituted phenylcarbinol, aminocarbonyl,

provided that E does not mean hydrogen or hydroxide, when G is phenyl, and their salts with inorganic acids

The invention relates to new chemical compounds with valuable properties, in particular to piperidinylmethyl derived chromane General formula (I)

< / BR>
where A is hydrogen or lower alkoxy,

E is hydrogen, hydroxyl, phenyl or piperidyl,

G phenyl not substituted or substituted with halogen and/or trifluoromethyl, fenoxaprop substituted by trifluoromethyl, benzyl, substituted phenylcarbinol, aminocarbonyl,

provided that E does not mean hydrogen or hydroxide, when G is phenyl, and their salts with inorganic acids

The invention relates to new derivatives of N-acyl-2,3-benzodiazepine General formula [I]

< / BR>
in which R is C1-6aliphatic acyl group, possibly substituted by methoxy, cyano, carboxyl, amino, C1-4-alkylamino, di(C1-4alkyl)amino, pyrrolidino, phthalimido or phenyl group or by one or more halogen(s), or R is a benzoyl, cyclopropanecarbonyl, C1-5-carbarnoyl or phenylcarbamoyl group, or R is absent when the N(3) and C(4) atoms there is a double bond, R1represents a hydrogen atom, or R1no, when between N(3) and C(4) atoms there is a double bond, R2represents C1-3alkyl, or R1and R2together represent a methylene group, and between the N(3) and C(4) atoms, no double bond, R3means a hydrogen atom or a C1-4-aliphatic acyl group, R4represents a hydrogen atom, a C1-6aliphatic acyl group, possibly substituted by methoxy, cyano, carboxyl, amino, C1-4-alkyl-amino-, di (C1-4alkyl) amino, pyrrolidino, phthalimido or phenyl group or by one or more halogen (s), and benzoyl, Palmitoyl, cyclo who can present valence bonds, provided that, when both of the substituent R3and R4represent hydrogen atoms between the N(3) and C(4) atoms, no double bonds, as well as the stereoisomers of these compounds along with acidic salts accession (when possible) and pharmaceutical compositions containing these compounds

The invention relates to the field of new biologically active compounds

FIELD: medicine.

SUBSTANCE: method involves carrying out hernia removal in intralaminar way. Posterior longitudinal ligament defect is covered with Tacho-Comb plate after having done disk cavity curettage. Subcutaneous fat fragment on feeding pedicle is brought to dorsal surface of radix and dural sac.

EFFECT: enhanced effectiveness of treatment; reduced risk of traumatic complications.

1 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: method involves intravenously administering 0.1-1% aqueous solution of khlorin, selected from group containing photolon, radachlorine or photoditazine at a dose of 0.2-0.5 mg/kg or 0.2-1% aqueous solution of porphyrin like photogem at a dose of 0.2-1 mg/kg. Laser irradiation of blood is carried out 5-15 min later after beginning photosensitizer injection into cubital vein of one arm via laser light guide set in advance in the cubital vein of the other arm during 10-40 min at wavelength of 661-666 nm and power of 20-50 mW one session per day during 3-10 days with the aqueous solution of khlorin used as the photosensitizer, or laser irradiation of blood with wavelength equal to 630-633 nm during 10-45 min with power of 20-50 mW one session per day with the aqueous solution of porphyrin used as the photosensitizer. Repeated intravenous administration of photosensitizer is carried out 1-3 months later combined with repeated laser irradiation of blood.

EFFECT: reduced risk of tumor cells dissemination and metastasis development.

2 cl

FIELD: medicine, narcology.

SUBSTANCE: one should detect satisfaction insufficiency syndrome due to performing genetic analysis by the presence of, at least, one of the genes coding the exchange of neuromediators being the constituents of human satisfaction system. One should compensate satisfaction insufficiency due to performing, at least, one complex of physical exercises. Moreover, in case of availability of pathological gene allele of dopamine D2 receptor and/or protein gene of reverse dopamine capture in patient one should apply the complex of physical exercises including those to provide sedative effect, and in case of availability of pathological gene allele of dopamine-beta-hydroxylase protein one should apply the complex of physical exercises including those that induce an activating effect. In case of availability of pathological gene allele of dopamine D2 receptor and/or protein gene of reverse dopamine capture one should apply additional food biologically active additives based upon amino acids being the precursors of neuromediators, such as taurine, D-, L-phenylalanine in combination with 5-hydroxytryptophan, hypericin and vitamin B6, and in case of pathological gene allele of dopamine-beta-hydroxylase protein one should additionally apply food biologically active additives based upon amino acids being the precursors of neuromediators, such as: taurine, tyrosine and/or dimethylaminoethanol, lecithin and group B-vitamins. The present innovation enables to take into account pathological disease mechanism.

EFFECT: higher efficiency of prophylaxis.

14 cl, 5 ex

FIELD: medicine, anesthesiology, resuscitation.

SUBSTANCE: one should perform puncturing of epidural space at Th12-L1 level. Through the lumen of puncture needle one should introduce catheter to move it cranially at the depth of 3 cm. After that one should inject 10 ml 05%-marcaine solution to perform repeated injections per 5.0 ml every 4 h during 1-8 d. The effect is achieved due to unloading minor cycle of circulation.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine, anesthesiology, resuscitation.

SUBSTANCE: one should perform puncturing of epidural space at Th12-L1 level. Through the lumen of puncture needle one should introduce catheter to move it cranially at the depth of 3 cm. After that one should inject 10 ml 05%-marcaine solution to perform repeated injections per 5.0 ml every 4 h during 1-8 d. The effect is achieved due to unloading minor cycle of circulation.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: organic chemistry, medicine, chemical-pharmaceutical industry, pharmacology, pharmacy.

SUBSTANCE: invention relates to a medicinal agent used for prophylaxis and treatment of diseases and disorders associated with dysfunction of benzodiazepine receptors. This medicinal agent comprises compound of the formula (I)

. Compound of the formula (I) elicits high cardioprotective, neurotrophic, renoprotective activity and enhanced bioavailability.

EFFECT: valuable medicinal properties of compounds.

5 cl, 1 tbl, 1 ex

Up!